BioSpace News Archive

RenovoRx, Inc today announced the acceptance of a clinical data abstract for the 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, held March 23-28 in Salt Lake City, Utah.

Biodexa Pharmaceuticals PLC, today announced the pricing of an underwritten public offering of units.

Enable Biosciences Inc. is elated to announce its receipt of a Phase IIB Small Business Innovation Research (SBIR) award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

The global biotechnology instruments market size was exhibited at USD 87.16 billion in 2022 and it is expected to hold around USD 128.4 billion by 2032, growing at a CAGR of 3.95% from 2023 to 2032.

According to Vision Research Reports, the global cell therapy raw materials market size was valued at USD 3.49 billion in 2022 and it is predicted to surpass around USD 31.28 billion by 2032 with a CAGR of 24.52% from 2023 to 2032. The cell therapy raw materials market in the United States was accounted for USD 1.3 billion in 2022.

Ablative Solutions, Inc., today announced that the TARGET BP I Pivotal Trial evaluating alcohol-mediated renal denervation with the Peregrine System ™ Kit met its primary endpoint, showing a statistically significant difference in 24-hour Ambulatory Blood Pressure between treatment and sham procedure at 3 months.

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that Nature Communications has published a 10x-conducted study using the Chromium Single Cell, Visium Spatial and Xenium In Situ platforms as part of an integrative approach to understand how tumor microenvironment differences influence invasiveness.

Alphatec Holdings, Inc. announced today that management will present at the J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, CA, at 3:45pm PT on January 10, 2024.

ECM Therapeutics announces a collaboration with the Louis J. Fox Center for Vision Restoration at the UPMC and Pitt Vision Institute led by José-Alain Sahel, MD, a distinguished professor and chair of the Department of Ophthalmology at the University of Pittsburgh School of Medicine.

Evaxion Biotech A/S, a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is pleased to announce a private placement financing to raise gross proceeds of approximately $5.3 million.